Item 5. OTHER INFORMATION
12K characters. Original on sec.gov · Markdown
Item 5. OTHER INFORMATION
During the three months ended March 31, 2025, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in item 408(a) of Regulation S-K.
ITEM 6. EXHIBITS
EXHIBIT INDEX
TO
FORM 10-Q
BIO-TECHNE CORPORATION
- Incorporated by reference; SEC File No. 000-17272
** Management contract or compensatory plan or arrangement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
|---|---|---|
| | BIO-TECHNE CORPORATION | |
| | | (Company) |
| | | |
| Date: May 8, 2025 | | /s/ Kim Kelderman |
| | | Kim Kelderman |
| | | President and Chief Executive Officer |
| | | |
| Date: May 8, 2025 | | /s/ James Hippel |
| | | James Hippel |
| | | Executive Vice President, Chief Financial Officer |
Previous: Item 4. MINE SAFETY DISCLOSURES
Sponsor Sponsor this sector. One slot per industry, shown on every filing in it. Details